Docteur RENAUD DESBARBIEUX

Bibliographie

• COVID-19 presentation and outcomes in patients with inflammatory rheumatic and musculoskeletal diseases receiving IL6-receptor antagonists prior to SARS-CoV-2 infection.

  2023

  ArticleJournal of Translational Autoimmunity

• COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study

  2021

  ArticleThe Lancet Rheumatology

Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).

Lieu de consultation

• CH BOULOGNE-SUR-MER

  Rue JACQUES MONOD, 62321 Boulogne-sur-Mer

  ☎ 0321993333Hospitalier🏥 Centre CH ↗🏥 Voir cet établissement

Tarifs & secteur de conventionnement

Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).

Prendre rendez-vous & contact

Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).

Articles de presse (3)

Source : Google News (recherche par nom complet — homonymes possibles, vérifier le contenu).

• Boulogne-sur-Mer : une onco-rhumatologue experte des lésions osseuses liées au cancer s’installe à l’hôpital - Nord Littoral

  📰 Nord Littoral · 23/04/2026

  <a href="https://news.google.com/rss/articles/CBMiygFBVV95cUxPcjQ5WEU1WjA2Y2dwU1YwcWM4YUtrRXZMdklHTXhpX2F0RjNGbVY1LUd0VUY2N1VuaUFubzJiX3V3OExFVHlWNlQzUlN3QkgzRVVRRkQtcGhhSkhjYWFWX1F1RFJWY2k1MV82NWdrU3U3RU5HZGp6NTBxMERnMjVOREtHMm54Q1FUaHJERmxtYUhzUlhpR2VQdE1EQ3puNHRLMFJBU0FZT3c2ODZIeDN0aEJYWFhmNkc0Qn

• Une onco-rhumatologue à l’hôpital de Boulogne pour mieux lutter contre le cancer et ses effets sur les articulations - La Voix du Nord

  📰 La Voix du Nord · 18/04/2026

  <a href="https://news.google.com/rss/articles/CBMizgFBVV95cUxPdE4xZ0pCbDA3bWN5V1NJd0YtVy1yRnlBZThVZUVDcmc5c2EzWmxuUFg0LUM2YmJ3OVdEeVkxdnV4NUlZYmQwYVI0ZUxUN3A3bkhqdE1GZnpsQUFRRGJwMFBBVXZqWVQ4UjBFVXlxTzZ0OTR4bnBQR0otLXFPTTlKZGJMckJQUGlQSXk5OERpSzRDd2Y3WElrQjRkZ2NxdjdnMkZrcXhGSzByTFJiX1FUYzVvSGNsQ2NrU2

• Le docteur Desbarbieux, nouveau rhumatologue à Duchenne et à l’institut Calot - La Voix du Nord

  📰 La Voix du Nord · 15/02/2019

  <a href="https://news.google.com/rss/articles/CBMixAFBVV95cUxNMnBvamFIS0s0bzFvcEEwNnI4QXJ1c2tPVDRwTWlzODJPN2RscWNTc1k5WC1Jc0dSNGRYMXk5YVJvdlZhem00SmEtb0tIeWJLb2t3YTkyck1Qck9OM2xWeGNWRU5RVmJWTG0xTF84Y2V0WXdzR3E2bjJ2Z0VRbzdSZWV6ZVdUVlhBdVhnbzlxT3dMMFlmTl9ER3lvU3dZSlNoc3RJUVZtcmdwMkRXMmJYVlhkU3RMcXk1VE

Top publications · les plus citées

• 1

  Retention, safety and efficacy of off-label conventional treatments and biologics for chronic calcium pyrophosphate crystal inflammatory arthritis

  Rheumatology (Oxford, England) · 2024

  📚 10 citations🎯 RCR 3.37Top 14% NIH🔓 Open Access📄 PDF gratuit ↗

  Lire l'abstract Crossref ↓

  Abstract Objectives Very little is known on the efficacy and safety of drugs for the management of chronic calcium pyrophosphate (CPP) crystal inflammatory arthritis. The objectives of this work were to describe the drugs used in the management of chronic CPP crystal inflammatory arthritis in expert European centres, and to examine treatment retention. Methods This was a retrospective cohort study. Charts from patients with a diagnosis of persistent inflammatory and/or recurrent acute CPP crystal arthritis were reviewed in seven European centres. Baseline characteristics were collected, and visits at months 3, 6, 12 and 24 included an assessment of treatment response and safety. Results One hundred and ninety-four treatments were initiated in 129 patients. Colchicine (used first-line in n = 73/86), methotrexate (used first-line in n = 14/36), anakinra (n = 27) and tocilizumab (n = 25) were the most prescribed treatments, while long-term corticosteroids, hydroxychloroquine, canakinumab and sarilumab were used occasionally. The 24-month on-drug retention was higher for tocilizumab (40%) than anakinra (18.5%) (P &amp;lt; 0.05), while the difference between colchicine (29.1%) and methotrexate (44.4%) was not statistically significant (P = 0.10). Adverse events led to 14.1% of colchicine discontinuations (100% of diarrhoea), 4.3% for methotrexate, 31.8% for anakinra and 20% for tocilizumab; all other discontinuations were related to insufficient response or losses to follow-up. Efficacy outcomes did not differ significantly between treatments throughout follow-up. Conclusion Daily colchicine is the first-line therapy used in chronic CPP crystal inflammatory arthritis, which is considered efficient in a third to half of cases. Second-line treatments include methotrexate and tocilizumab, which have higher retention than anakinra.

• 2

  Does bevacizumab increase joint pain in patients with cancer? Results of the prospective observational BEVARTHRALGIA study

  Cancer chemotherapy and pharmacology · 2021

  📚 5 citations🩺 Clinique
• 3

  Spondylodiscitis caused by Bordetella holmesii, a misrecognized pathogen emerging in invasive infections

  International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2018

  📚 2 citations🔓 Open Access

Publications scientifiques (4) — classées par pathologie

Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).

Partager cette fiche